Paula Paulo

Porto, Portugal

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape.

CD276 immature glycosylation drives colorectal cancer aggressiveness and T cell mediated immune escape.

Journal: Cell communication and signaling : CCS
Published: August 21, 2025

EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer.

EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer.

Journal: Molecular oncology
Published: October 11, 2024

Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.

Multilevel plasticity and altered glycosylation drive aggressiveness in hypoxic and glucose-deprived bladder cancer cells.

Journal: iScience
Published: November 27, 2023

BUB1B monoallelic germline variants contribute to prostate cancer predisposition by triggering chromosomal instability.

BUB1B monoallelic germline variants contribute to prostate cancer predisposition by triggering chromosomal instability.

Journal: Journal of biomedical science
Published: August 03, 2023

Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.

Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.

Journal: Genes, chromosomes & cancer
Published: March 28, 2023

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.

Journal: Nature genetics
Published: August 21, 2022

Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene.

Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene.

Journal: British journal of cancer
Published: May 24, 2022

Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.

Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.

Journal: Theranostics
Published: September 23, 2021

Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.

Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.

Journal: Journal of experimental & clinical cancer research : CR
Published: March 15, 2021

Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Journal: Nature genetics
Published: January 21, 2021

Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.

Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.

Journal: European urology oncology
Published: October 27, 2020

The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor.

The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor.

Journal: Cancers
Published: September 15, 2020
Showing 1-12 of 41

Last Updated: 09/26/2026